Cystic Fibrosis Agents Clinical Prior Authorization to Include Trikafta Criteria Starting Feb 24, 20

Cystic Fibrosis Agents Clinical Prior Authorization to Include Trikafta Criteria Starting Feb 24, 2020

FirstCare implemented the Trikafta criteria within the existing Cystic Fibrosis Agents clinical prior authorization on Feb 24, 2020.  All clinical edit criteria can be found here.

The Texas Drug Utilization Board approved the criteria for Trikafta at the Jan 2020 meeting.  Trikafta is a cystic fibrosis transmembrane conductance regulator (CFTR) modulating agent.  As part of the criteria is a check for duplicative or concurrent therapies with another CTFR modulating agent.  The board recommended the inclusion of this step to the criteria for all CFTR modulator agents.

Send to a Friend

* Required field

Captcha The math problem above is intended to reduce spam.